CRA provided expert reports and testimony in several cases involving improper diversion of diabetes test strips. CRA’s damages analyses quantified the difference in profits earned on legitimate sales of test strips in the U.S. retail market as compared to profits earned on the diverted test strips (for example, those sold in international markets or those intended for other patient groups in the U.S.
Recent trends in Rule 702 decisions – 2024
In this CRA Insights, we update the Rule 702 decision trends in last year’s Insights with 2023 data.[1] We also provide descriptions of four specific...